| Literature DB >> 36105170 |
Shi-Jun Yin1, Xi Zhou1, Li-Jing Peng1, Fang Li2, Guo-Can Zheng2, Feng-Qing Yang1, Yuan-Jia Hu3.
Abstract
An innovative sandwich-structural Fe-based metal-organic framework magnetic material (Fe3O4@SW-MIL-101-NH2) was fabricated using a facile solvothermal method. The characteristic properties of the material were investigated by field emission scanning electron microscopy, transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy, Fourier transform infrared spectroscopy, X-ray powder diffraction, vibrating sample magnetometry, and Brunauer-Emmett-Teller measurements. Fe3O4@SW-MIL-101-NH2 is associated with advantages, such as robust magnetic properties, high specific surface area, and satisfactory storage stability, as well as good selective recognition ability for chlorogenic acid (CA) and its metabolites via chelation, hydrogen bonding, and π-interaction. The results of the static adsorption experiment indicated that Fe3O4@SW-MIL-101-NH2 possessed a high adsorption capacity toward CA and its isomers, cryptochlorogenic acid (CCA) and neochlorogenic acid (NCA), and the adsorption behaviors were fitted using the Langmuir adsorption isotherm model. Then, a strategy using magnetic solid-phase extraction (MSPE) and ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF MS/MS) was developed and successfully employed for the selective pre-concentration and rapid identification of CA metabolites in rat plasma, urine, and feces samples. This work presents a prospective strategy for the synthesis of magnetic adsorbents and the high-efficiency pretreatment of CA metabolites.Entities:
Keywords: Chlorogenic acid; Magnetic solid-phase extraction; Metabolic pathway; Metal-organic framework; Sandwich structure
Year: 2022 PMID: 36105170 PMCID: PMC9463528 DOI: 10.1016/j.jpha.2022.01.002
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Fig. 1Scanning electron microscopy (SEM) images of (A) MIL-101-NH2, (B and C) Fe3O4@MIL-101-NH2, and (D) Fe3O4@SW-MIL-101-NH2; transmission electron microscopy (TEM) images of (E) Fe3O4@MIL-101-NH2 and (F) Fe3O4@SW-MIL-101-NH2; (G and H) energy-dispersive X-ray spectroscopy results of the main elements.
Fig. 2(A) The Fourier transform infrared (FT-IR) spectra and (B) X-ray diffraction (XRD) of Fe3O4, MIL-101-NH2, Fe3O4@MIL-101-NH2 and Fe3O4@SW-MIL-101-NH2. (C) Magnetization hysteresis loops of Fe3O4 and Fe3O4@SW-MIL-101-NH2. The inset picture is the disperse state of the Fe3O4@SW-MIL-101-NH2 adsorbent in aqueous solution and under an external magnetic force. (D) Nitrogen adsorption-desorption isotherm of Fe3O4@SW-MIL-101-NH2; inset shows the pore-size distribution of Fe3O4@SW-MIL-101-NH2.
Fig. 3Effects of (A) the amount of adsorbent, (B) extraction time, (C) extraction temperature, (D) ion strength (KH2PO4–K2HPO4), (E) ion strength (NaCl), (F) pH value (10.0 mM NaOH–HCl), and mixed reference compounds solutions at different pH conditions (inset) on the adsorption percentage. Effects of (G) elution solvent type and (H) elution time on the recovery of analytes using Fe3O4@SW-MIL-101-NH2 as an adsorbent. CA: chlorogenic acid; CCA: cryptochlorogenic acid; NCA: neochlorogenic acid.
The linear relationship and parameters of Langmuir and Freundlich adsorptions.
| Compounds | Langmuir | Freundlich | ||||||
|---|---|---|---|---|---|---|---|---|
| Regressive equation | Qmax (mg/g) | Regressive equation | ||||||
| NCA | 15.4 | 0.45 | 0.992 | 175.8 | 0.09 | 0.949 | ||
| CA | 37.0 | 0.32 | 0.994 | 354.8 | 0.22 | 0.957 | ||
| CCA | 43.5 | 0.23 | 0.998 | 376.7 | 0.23 | 0.939 | ||
0.1 < 1/n ≤ 0.5 represents that the adsorption is very easy to perform; 0.5 < 1/n ≤ 1 represents that the adsorption is easy to perform; 1 > 1/n represents that the adsorption is difficult to perform. CA: chlorogenic acid; CCA: cryptochlorogenic acid; NCA: neochlorogenic acid.
Mass spectrometry and chromatography information of chlorogenic acid and its metabolites.
| No. | Retention time (min) | Formula | [M−H]− ( | MS/MS fragment ion | Metabolic pathway | Real samples | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theoretical | Experimental | Error (mDa) | Feces | Plasma | Urine | |||||||||
| 0−4 h | 4−8 h | 0.5 h | 4 h | 8 h | 0−4 h | 4−8 h | ||||||||
| C0 | 15.952 | C16H18O9 | 353.3046 | 353.1407 | −0.46 | 353.1407 ([M−H]−), 190.9291 ([M−H–C9H6O3]−), 178.9049 ([M−H–C7H10O5]−), 135.1120 ([M−H–C7H10O5–CO2]−) | Parent (CA) | + | + | + | + | + | + | + |
| C1 | 13.550 | C9H8O4 | 179.1518 | 179.1082 | −0.24 | 179.1082 ([M−H]−), 135.1371 ([M−H–CO2]−), 117.7631 ([M−H–CO2–OH]−), 93.0342 ([M−H–CO2–C2H2O]−) | Hydrolysis to caffeic acid | – | – | + | + | + | – | – |
| C2 | 12.969 | C11H10O5 | 221.1889 | 221.1540 | −0.16 | 221.1540 ([M−H]−), 179.1226 ([M−H–C2H2O]−) | Acetylation of C1 | + | + | + | + | + | + | + |
| C3 | 13.536 | C11H11NO5 | 236.2036 | 236.1730 | −0.13 | 236.1730 ([M−H]−), 162.0954 ([M−H–C2H4NO2]−), 93.0336 ([M−H–C5H5NO4]−) | Glycine conjugation of C1 | – | + | + | + | + | + | + |
| C4 | 16.141 | C16H18O9 | 353.3046 | 353.2109 | −0.27 | 353.2109 ([M−H]−), 190.9096 ([M−H–C9H6O3]−), 178.9049 ([M−H–C7H10O5]−), 135.1120 ([M−H–C7H10O5–CO2]−) | 4-caffeoylquinic acid | + | + | + | + | + | + | + |
| C5 | 17.095 | C16H20O9 | 355.3204 | 355.1577 | −0.46 | 355.1577 ([M−H]−), 191.2094 ([M−H–C9H8O3]−) | Reduction | + | + | + | + | + | + | + |
| C6 | 17.083 | C15H18O10 | 357.2930 | 357.1599 | −0.37 | 357.1599 ([M−H]−), 181.0272 ([M−H–C6H8O6]−) | Glucuronidation of C1 and reduction | + | + | – | – | – | – | – |
| C7-1 | 14.321 | C17H20O9 | 367.3314 | 367.2422 | −0.24 | 367.2422 ([M−H]−), 193.2617 ([M−H–C7H10O5]−), 191.2581 ([M−H–C10H8O3]−), 173.2477 ([M−H–C10H8O3–H2O]−), 134.0059 ([M−H–C9H13O7]−) | Methylation | + | + | + | + | + | + | + |
| C7-2 | 16.872 | C17H20O9 | 367.3314 | 367.2422 | −0.24 | 367.2422 ([M−H]−), 193.2617 ([M−H–C7H10O5]−), 191.2581 ([M−H–C10H8O3]−), 173.2477 ([M−H–C10H8O3–H2O]−), 134.0059 ([M−H–C9H13O7]−) | Methylation | + | + | + | + | + | + | – |
| C8-1 | 17.586 | C16H18O10 | 369.3040 | 369.1726 | −0.36 | 369.1732 ([M−H]−), 192.9726 ([M−H–C6H8O6]−), 134.0127 ([M−H–C6H8O6–C2H3O2]−) | Methylation and glucuronidation of C1 | + | + | + | + | + | + | – |
| C8-2 | 17.809 | C16H18O10 | 369.3040 | 369.1727 | −0.36 | 369.1727 ([M−H]−), 193.0284 ([M−H–C6H8O6]−), 149.1840 ([M−H–C6H8O6–CO2]−) | Methylation and glucuronidation of C1 | – | – | – | – | – | – | + |
| C8-3 | 7.426 | C16H18O10 | 369.3040 | 369.1732 | −0.35 | 369.1726 ([M−H]−), 193.0281 ([M−H–C6H8O6]−), 149.1838 ([M−H–C6H8O6–CO2]−), 134.0125 ([M−H–C6H8O6–C2H3O2]−) | Methylation and glucuronidation of C1 | + | + | + | + | + | – | + |
| C9 | 16.237 | C16H20O10 | 371.3198 | 371.2193 | −0.27 | 371.2193 ([M−H]−), 195.3327 ([M−H–C6H8O6]−) | Methylation, glucuronidation of C1 and reduction | + | – | – | + | – | – | + |
| C10 | 13.228 | C20H27NO11S | 488.4912 | 488.5079 | 0.03 | 488.5079 ([M−H]−), 387.3297 ([M−H–C4H7NO2]−), 367.3683 ([M−H–C3H7NO2S]−), 191.2087 ([M−H–C3H7NO2S–C10H8O3]−), 181.0788 ([M−H–C3H7NO2S–C7H6O6]−), 120.0823 ([M−H–C17H20O9]−) | Methylation and cysteine conjugation | – | + | + | + | + | + | + |
| C11 | 11.803 | C20H27N3O10S | 500.5053 | 500.2758 | −0.46 | 500.2758 ([M−H]−), 320.8935 ([M−H–C9H7O4]−), 303.2319 ([M−H–C9H7O4–H2O]−) | Methylation and glutathione Michael addition of C1 | – | – | – | – | – | – | + |
| C12 | 12.118 | C22H30N2O12S | 545.5430 | 545.5468 | 0.01 | 545.5468 ([M−H]−), 367.0912 ([M−H–C5H8O3N2S–2H]−), 191.3247 ([M−H–C5H8O3N2S–C10H10O3]−), 93.2103 ([M−H–C5H8O3N2S–CH3–C7H10O6–C3H3O2)−]), 85.0024 ([M−H–C5H8O3N2S–C10H9O3–C3H7O4]−) | Methylation and cysteinylglycine conjugation of C1 | + | + | + | + | + | + | + |
+: detected; −: not detected.
Fig. 4Proposed biotransformation pathways of chlorogenic acid in rat. C0–C12 are the same as those in Table 2.
Comparison of the developed method with other reported metabolic sample pretreatment methods.
| Pretreatment method | Extraction conditions | Analytical method | Time (min) | Application | Sample | Refs. |
|---|---|---|---|---|---|---|
| LLE | 100 μL of sample and 300 μL of acetonitrile | UPLC-Q-TOF MS | >20 | Quercetin-3- | Rat plasma, urine, and bile | [ |
| LLE | Dilute 200 mL of sample and CHCl3 (600 mL)- | HPLC-SPE-NMR coupled with HPLC-HRESIMS | – | Sinisan metabolites | Rat urine | [ |
| SPE | 0.5 mL of sample eluted with 3.2 mL of MeOH | UPLC-ESI-Q-TOF MS | – | Radix Paeoniae Alba extract metabolites | Rat bile, plasma, and urine | [ |
| MMIP | 100 mg of feces eluted with methanol | LC-LTQ-Orbitrap-MS | 73 | Rat feces | [ | |
| MSPE | 5 mL of sample-20 mg of HCP/Fe3O4 eluted with 2 mL of ACN | LC-MS/MS | 10 | Nitrofuran metabolites | Honey | [ |
| MSPE | 20 mg of magnetic COFs eluted with 5 mL of MeOH | LC-MS/MS | 29 | Aromatic amine metabolites | Human urine | [ |
| MSPE | 1.0 mL of sample and 2.0 mg of adsorbent eluted with mixed solution containing 0.8 mL of Na3PO4 (50 mM) and 0.2 mL of MeOH | UPLC-Q-TOF MS/MS | 12.5 | Chlorogenic acid metabolites | Rat plasma, urine, and feces | This work |
COFs: covalent organic frameworks; HCP: hypercrosslinked polystyrene; HPLC-HRESIMS: high performance liquid chromatography-high resolution electrospray ionization mass spectrometry; HPLC-SPE-NMR: high performance liquid chromatography-solid phase extraction- nuclear magnetic resonance; LC-LTQ-Orbitrap-MS: liquid chromatography-linear ion trap-orbitrap mass spectrometry; LC-MS/MS: liquid chromatography-tandem mass spectrometry; LLE: liquid-liquid extraction; MMIP: magnetic molecular imprinting; MSPE: magnetic solid-phase extraction; UPLC-ESI-Q-TOF MS: ultra-performance liquid chromatography-electrospray ionization with quadrupole time-of-flight tandem mass spectrometry; SPE: solid phase extraction.